Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001493152-25-029834·Inhibikase Therapeutics, Inc.
Schedule 13G ownership disclosure
Inhibikase Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 45719W205
Event date: 2025-12-23
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Trails Edge Capital Partners, LP
Shares: 6,145,198.00 · Class: 5.1%
- Trails Edge Biotechnology Master Fund, LP
Shares: 6,145,198.00 · Class: 5.1%
- Ortav Yehudai
Shares: 6,145,198.00 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001493152-25-029834
- Form type
- SCHEDULE 13G
- Filer
- Inhibikase Therapeutics, Inc.
- CIK
- CIK 1750149
- Filed
- Dec 31, 2025
- Reporting period
- Dec 23, 2025
- Description
- Schedule 13G beneficial ownership